Novel features of nitric oxide, endothelial nitric oxide synthase, and atherosclerosis

Louis J. Ignarro, Claudio Napoli

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

There is a complex pathophysiologic scenario involving nitric oxide (NO), endothelial nitric oxide synthase (eNOS), and the development of atherosclerosis and unstable atheroma. Endothelial damage induced by atherosclerosis leads to the reduction in bioactivity of ENOS with subsequent impaired release of NO. An important mechanism is local enhanced degradation of NO by increased generation of reactive oxygen species and other free radicals, with subsequent cascade of oxidation-sensitive mechanisms in the arterial wall. Novel molecular approaches have resulted in the development of new strains of mice lacking eNOS. These experimental models will help to understand how to implement NO-based therapies against atherosclerosis. L-arginine, the precursor of NO, has demonstrated beneficial effects in atherosclerosis and disturbed shear stress. The target or goal for new drugs should be the complete restoration of NO-mediated signaling pathways in atherosclerotic arteries.

Original languageEnglish
Pages (from-to)281-287
Number of pages7
JournalCurrent Atherosclerosis Reports
Volume6
Issue number4
Publication statusPublished - Jul 2004

Fingerprint

Nitric Oxide Synthase Type III
Atherosclerosis
Nitric Oxide
Atherosclerotic Plaques
Free Radicals
Arginine
Reactive Oxygen Species
Theoretical Models
Arteries
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Novel features of nitric oxide, endothelial nitric oxide synthase, and atherosclerosis. / Ignarro, Louis J.; Napoli, Claudio.

In: Current Atherosclerosis Reports, Vol. 6, No. 4, 07.2004, p. 281-287.

Research output: Contribution to journalArticle

@article{ecb64499c5c94953b8264032adc3aa50,
title = "Novel features of nitric oxide, endothelial nitric oxide synthase, and atherosclerosis",
abstract = "There is a complex pathophysiologic scenario involving nitric oxide (NO), endothelial nitric oxide synthase (eNOS), and the development of atherosclerosis and unstable atheroma. Endothelial damage induced by atherosclerosis leads to the reduction in bioactivity of ENOS with subsequent impaired release of NO. An important mechanism is local enhanced degradation of NO by increased generation of reactive oxygen species and other free radicals, with subsequent cascade of oxidation-sensitive mechanisms in the arterial wall. Novel molecular approaches have resulted in the development of new strains of mice lacking eNOS. These experimental models will help to understand how to implement NO-based therapies against atherosclerosis. L-arginine, the precursor of NO, has demonstrated beneficial effects in atherosclerosis and disturbed shear stress. The target or goal for new drugs should be the complete restoration of NO-mediated signaling pathways in atherosclerotic arteries.",
author = "Ignarro, {Louis J.} and Claudio Napoli",
year = "2004",
month = "7",
language = "English",
volume = "6",
pages = "281--287",
journal = "Current Atherosclerosis Reports",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "4",

}

TY - JOUR

T1 - Novel features of nitric oxide, endothelial nitric oxide synthase, and atherosclerosis

AU - Ignarro, Louis J.

AU - Napoli, Claudio

PY - 2004/7

Y1 - 2004/7

N2 - There is a complex pathophysiologic scenario involving nitric oxide (NO), endothelial nitric oxide synthase (eNOS), and the development of atherosclerosis and unstable atheroma. Endothelial damage induced by atherosclerosis leads to the reduction in bioactivity of ENOS with subsequent impaired release of NO. An important mechanism is local enhanced degradation of NO by increased generation of reactive oxygen species and other free radicals, with subsequent cascade of oxidation-sensitive mechanisms in the arterial wall. Novel molecular approaches have resulted in the development of new strains of mice lacking eNOS. These experimental models will help to understand how to implement NO-based therapies against atherosclerosis. L-arginine, the precursor of NO, has demonstrated beneficial effects in atherosclerosis and disturbed shear stress. The target or goal for new drugs should be the complete restoration of NO-mediated signaling pathways in atherosclerotic arteries.

AB - There is a complex pathophysiologic scenario involving nitric oxide (NO), endothelial nitric oxide synthase (eNOS), and the development of atherosclerosis and unstable atheroma. Endothelial damage induced by atherosclerosis leads to the reduction in bioactivity of ENOS with subsequent impaired release of NO. An important mechanism is local enhanced degradation of NO by increased generation of reactive oxygen species and other free radicals, with subsequent cascade of oxidation-sensitive mechanisms in the arterial wall. Novel molecular approaches have resulted in the development of new strains of mice lacking eNOS. These experimental models will help to understand how to implement NO-based therapies against atherosclerosis. L-arginine, the precursor of NO, has demonstrated beneficial effects in atherosclerosis and disturbed shear stress. The target or goal for new drugs should be the complete restoration of NO-mediated signaling pathways in atherosclerotic arteries.

UR - http://www.scopus.com/inward/record.url?scp=5444239280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5444239280&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 281

EP - 287

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

SN - 1523-3804

IS - 4

ER -